10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trialCourtney D. DiNardo, Marina Konopleva, Ghayas C. Issa et al.|The Lancet Haematology|2020Cited by 330
Neoadjuvant Pembrolizumab in Localized Microsatellite Instability High/Deficient Mismatch Repair Solid TumorsKaysia Ludford, Michael J. Overman, Won Jin Ho et al.|Journal of Clinical Oncology|2023Cited by 193
Molecular Profiling of Hepatocellular Carcinoma Using Circulating Cell-Free DNAAhmed O. Kaseb, Razelle Kurzrock, Nora Sánchez et al.|Clinical Cancer Research|2019Cited by 76
Long-term follow-up of azacitidine, venetoclax, and gilteritinib in patients with newly diagnosed FLT3-mutated Acute Myeloid LeukemiaRoberta S. Azevedo, Nicholas J. Short, Naval Daver et al.|Blood|2025Cited by 2
Identification of an optimal absolute lymphocyte count before bispecific antibody therapy for large B-cell lymphoma: A collaborative US bispecific consortium StudyKunhwa Kim, Ajay Major, Zhouxuan Li et al.|Blood|2025Cited by 0